STOCK TITAN

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) SEC Filings, Jul-Aug 2026

KMTS NASDAQ

Kestra Medical Technologies filings document the public-company disclosures of a Bermuda-incorporated medical technology issuer listed on Nasdaq under KMTS. Its Form 8-K reports have furnished quarterly and annual financial results, revenue guidance, and Regulation FD disclosures tied to the ASSURE WCD and ACE-PAS post-approval study results.

The company’s proxy materials and annual meeting filings cover board elections, independent auditor ratification, shareholder voting results, and equity compensation matters, including the 2025 Employee Stock Purchase Plan. These records also identify governance procedures and formal shareholder actions for the wearable defibrillator and digital health business.

Rhea-AI Summary

Kestra Medical Technologies reports that an affiliate plans to sell 2,380 shares of common stock through Merrill Lynch on August 3, 2026 on NASDAQ, with an indicated aggregate market value of $56,551.44. These shares relate to performance share unit awards that vested on July 17, 2026 and were granted under the issuer’s equity compensation plan. The notice also lists prior sales by Timothy Moran of 4,117 shares for $93,758.64 on July 30, 2026 and 8,759 shares for $198,000.29 on July 31, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.09%
Tags
other
-
Rhea-AI Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. reports a planned sale of 13,017 shares of common stock through Merrill Lynch on July 31, 2026, listed on NASDAQ. These shares were acquired on July 17, 2026 as a performance stock issuance granted under the issuer’s equity compensation plan. Over the prior three months, reporting person Brian Webster sold multiple blocks of common shares, including 15,000-share transactions on April 15, May 15, June 15, and July 15, 2026, and additional sales of 7,857 and 8,948 shares on July 30 and July 31, 2026, respectively, each with stated aggregate sale values.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.09%
Tags
other
-
Rhea-AI Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. insider Alfred J Ford has filed to sell common stock under Rule 144. The planned sale covers 8,681 shares of common stock through Merrill Lynch, with an aggregate market value of $196,284.58, and is expected on July 31, 2026 on NASDAQ.

The shares relate to performance share unit awards that vested on July 17, 2026 and were granted under the issuer’s equity compensation plan. Over the past three months, Ford has already sold 5,936 shares for an aggregate sale price of $135,120.73.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
other
Rhea-AI Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. officer Mahboob Vaseem's notice lists 8,817 common shares for sale, with an aggregate market value of $199,344.62 and an approximate sale date of July 31, 2026. The shares were acquired July 17, 2026, through vesting of performance share unit awards under the issuer's equity compensation plan. A separate past-three-months table reports 3,980 shares sold July 30 for gross proceeds of $90,560.62.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
other
-
Rhea-AI Summary

Kestra Medical Technologies, Ltd. (KMTS) has a notice from insider Traci Umberger indicating an intent to sell up to 8,752 shares of common stock through Merrill Lynch on or after July 31, 2026 on NASDAQ. These shares are tied to the July 17, 2026 vesting of performance share unit awards, granted as part of the company’s equity compensation program.

The filing also reports that Umberger sold 5,887 shares of common stock on July 30, 2026 for 133,892.22 during the prior three months, providing recent trading history associated with this insider’s holdings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
other
-
Rhea-AI Summary

Kestra Medical Technologies, Ltd. has a notice of proposed sale of common stock by insider Timothy Moran under Rule 144. The filing lists up to 8,759 shares of common stock to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $198,000.29 as of July 31, 2026. These shares relate to the vesting of performance share unit awards granted under the issuer’s equity compensation plan on July 17, 2026. The filing also reports that on July 30, 2026, Moran sold 4,117 shares of common stock for $93,758.64 within the past three months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
other
Rhea-AI Summary

Kestra Medical Technologies, Ltd. (KMTS) reports a planned sale of up to 8,948 common shares through Merrill Lynch, to be sold on or after July 31, 2026 on NASDAQ, with an approximate aggregate market value of $202,259.77. These shares were issued on July 17, 2026 as a performance stock issuance granted under the issuer’s equity compensation plan. The filing also lists recent sales by Brian Webster over the past three months, including 15,000 common shares on each of April 15, May 15, June 15, and July 15, 2026, and an additional 7,857 shares on July 30, 2026, for stated proceeds on each date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
other
-
Rhea-AI Summary

Kestra Medical Technologies, Ltd. has a proposed sale of 4,117 shares of its common stock through Merrill Lynch on NASDAQ, dated 07/30/2026. The shares relate to performance share unit awards that vested on 07/17/2026 and were granted under the issuer’s equity compensation plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
other
-
Rhea-AI Summary

Kestra Medical Technologies, Ltd. reports a planned sale of 7,857 shares of common stock through Merrill Lynch on July 30, 2026. These shares relate to a performance stock issuance dated July 17, 2026, granted under an issuer equity compensation plan. Recent sales over the past three months include four transactions of 15,000 common shares each by Brian Webster.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
other
Rhea-AI Summary

Kestra Medical Technologies, Ltd. filed to permit the sale of up to 5,887 shares of common stock through Merrill Lynch on or about July 30, 2026 on NASDAQ. These shares relate to the vesting of performance share unit awards on July 17, 2026, originally granted as part of issuer equity compensation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
other

FAQ

How many KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) SEC filings are available on StockTitan?

StockTitan tracks 121 SEC filings for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)?

The most recent SEC filing for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) was filed on November 5, 2026.